What is BofA Securities's price target for PRLD?

BofA Securities's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $6, from its action on Nov 21, 2022.

What is BofA Securities's rating on PRLD?

BofA Securities rates PRLD Underperform, a bearish rating, as of Nov 21, 2022.

When did BofA Securities last change its view on PRLD?

On Nov 21, 2022, BofA Securities downgrades to Underperform from Neutral, price target $8 to $6.

Analyst firms · BofA Securities · PRLD

BofA Securities PRLD price target and rating history

Prelude Therapeutics Incorporated (PRLD) · Health Care

BofA Securities rates Prelude Therapeutics Incorporated (PRLD) Underperform with a $6 price target, as of its latest action on Nov 21, 2022. It has published 3 rating actions on PRLD since July 2021, including 1 upgrade and 2 downgrades.

Current rating: Underperform
Price target: $6
Median target, all firms: Too few
Actions on PRLD: 3

BofA Securities price target on PRLD

BofA Securities price target on PRLD, each point a stated target, July 2021 to November 2022.

Every BofA Securities rating on PRLD

Nov 21, 2022
DowngradeBofA Securities downgrades to Underperform from Neutral, price target $8 to $6
Mar 15, 2022
DowngradeBofA Securities downgrades to Neutral from Buy, price target $50 to $10
Jul 27, 2021
UpgradeBofA Securities upgrades to Buy from Neutral, price target $60

Questions about BofA Securities and PRLD

What is BofA Securities's price target for PRLD?: BofA Securities's latest stated price target for Prelude Therapeutics Incorporated (PRLD) is $6, from its action on Nov 21, 2022.
What is BofA Securities's rating on PRLD?: BofA Securities rates PRLD Underperform, a bearish rating, as of Nov 21, 2022.
When did BofA Securities last change its view on PRLD?: On Nov 21, 2022, BofA Securities downgrades to Underperform from Neutral, price target $8 to $6.

More PRLD rating histories

All BofA Securities ratings PRLD news and filings Every analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.